Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8473938 | 0.80 | RAB9A (0.55) | RAB9ANPC1ALDH1A1MAPTCTSD | |
| SCHEMBL9101 | 0.79 | RAB9A (0.58) | RAB9ANPC1ALDH1A1MAPTCTSD | |
| SCHEMBL7952 | 0.79 | RAB9A (0.58) | RAB9ANPC1ALDH1A1MAPTCTSD | |
| SCHEMBL615386 | 0.78 | RAB9A (0.57) | RAB9ANPC1ALDH1A1MAPTCTSD | |
| SCHEMBL5486501 | 0.78 | RAB9A (0.57) | RAB9ANPC1ALDH1A1MAPTCTSD | |
| SCHEMBL1590640 | 0.78 | ALDH1A1 (0.49) | RAB9ANPC1ALDH1A1MAPTKDM4E | |
| SCHEMBL1193711 | 0.78 | TSHR (0.56) | RAB9ANPC1ALDH1A1MAPTKDM4E | |
| SCHEMBL28674881 | 0.78 | NPC1 (0.61) | RAB9ANPC1ALDH1A1MAPTCTSD | |
| SCHEMBL50229 | 0.76 | MAPT (0.64) | RAB9ANPC1ALDH1A1MAPTCTSD | |
| SCHEMBL28558451 | 0.76 | RAB9A (0.54) | RAB9ANPC1ALDH1A1MAPTCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745015-B1 | BICYCLIC AROMATIC SULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-02-17 | — | — | EP | claimed |
| JP-2011525181-A | — | — | 2011-09-15 | — | — | JP | claimed |
| EP-1496930-B1 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | UNIV CALIFORNIA (US) | 2011-07-20 | — | — | EP | claimed |
| EP-2300038-A2 | IMPROVED PEPTIDE MEDIATORS OF CHOLESTEROL EFFLUX | The Regents of the University of California (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009155366-A2 | IMPROVED PEPTIDE MEDIATORS OF CHOLESTEROL EFFLUX | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-12-23 | — | — | WO | claimed |
| EP-1214445-A4 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN INC (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1496930-A4 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | UNIV CALIFORNIA (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1318828-A4 | ORALLY ADMINISTERED PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | UNIV CALIFORNIA (US) | 2005-04-27 | — | — | EP | claimed |
| EP-1496930-A2 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | The Regents of The University of California (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003086326-A2 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-10-23 | — | — | WO | claimed |
| EP-1318828-A1 | ORALLY ADMINISTERED PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | The Regents of the University of California (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1214445-A1 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN, INC. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2002015923-A1 | ORALLY ADMINISTERED PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2001018238-A1 | COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF | ONCOIMMUNIN, INC. (US) | 2001-03-15 | — | — | WO | claimed |
| EP-0794959-B1 | AMINO ACIDS FOR MAKING BETIDES AND METHODS OF SCREENING AND MAKING BETIDE LIBRARIES | SALK INST FOR BIOLOGICAL STUDI (US) | 2000-04-05 | — | — | EP | claimed |
| US-5681928-A | ACYLATION, ALKYLATION OF AN AMINOGLYCINE; INSERTION INTO PEPTIDE | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1997-10-28 | — | — | US | claimed |
| EP-0794959-A1 | AMINO ACIDS FOR MAKING BETIDES AND METHODS OF SCREENING AND MAKING BETIDE LIBRARIES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1997-09-17 | — | — | EP | claimed |
| WO-1996018642-A1 | AMINO ACIDS FOR MAKING BETIDES AND METHODS OF SCREENING AND MAKING BETIDE LIBRARIES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-06-20 | — | — | WO | claimed |
| US-4132712-A | Antibacterial agents | BEECHAM GROUP LIMITED (GB) | 1979-01-02 | — | — | US | claimed |
| US-12017989-B2 | Controlled release pharmaceutical formulations | UNITED THERAPEUTICS CORPORATION (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240166661-A1 | Spiropiperidine Derivatives | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11878982-B2 | Spiropiperidine derivatives | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| EP-4175664-A2 | PROSTATE NEOANTIGENS AND THEIR USES | Janssen Biotech, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| CN-114008065-A | Glycyrrhetinic acid derivatives for treating hyperkalemia | 阿德利克斯股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2022009052-A2 | PROSTATE NEOANTIGENS AND THEIR USES | JANSSEN BIOTECH, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20210317066-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | UNITED THERAPEUTICS CORPORATION (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210284651-A1 | Spiropiperidine Derivatives | CEPHALON LLC | 2021-09-16 | — | — | US | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| US-11046707-B2 | Spiropiperidine derivatives | 89BIO LTD (IL) | 2021-06-29 | — | — | US | disclosed |
| US-11001551-B2 | Controlled release pharmaceutical formulations | UNITED THERAPEUTICS CORPORATION (US) | 2021-05-11 | — | — | US | disclosed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-3784262-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. Hoffmann-La Roche AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | 89BIO LTD (IL) | 2021-02-16 | — | — | US | disclosed |
| EP-3310773-B1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-12-02 | — | — | EP | disclosed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | disclosed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | disclosed |
| US-10640481-B2 | Methods for producing Beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200062691-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | UNITED THERAPEUTICS CORPORATION (US) | 2020-02-27 | — | — | US | disclosed |
| CN-110785418-A | Isoindolinone derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-110770229-A | Benzofuran compounds as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200031840-A1 | SPIROPIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| US-10494327-B2 | Controlled release pharmaceutical formulations | UNITED THERAPEUTICS CORPORATION (US) | 2019-12-03 | — | — | US | disclosed |
| EP-3554637-A1 | SPIROPIPERIDINE DERIVATIVES | 89Bio Ltd. (IL) | 2019-10-23 | — | — | EP | disclosed |
| US-10420816-B1 | Immunotherapy against several tumors including gastrointestinal and gastric cancer | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20190202797-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2019-05-23 | — | — | US | disclosed |
| US-10246430-B2 | Methods for producing Beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2019-04-02 | — | — | US | disclosed |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2019-03-05 | — | — | US | disclosed |
| CN-109134610-A | A kind of peptides, its application and the composition containing it | 凯惠科技发展(上海)有限公司 | 2019-01-04 | — | — | CN | disclosed |
| US-20180265490-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2018-09-20 | — | — | US | disclosed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | disclosed |
| US-10005753-B2 | Methods for producing beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2018112204-A1 | SPIROPIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| CN-105153188-B | The fused ring analogs of antifibrotic agents | 法博太科制药有限公司 | 2018-06-01 | — | — | CN | disclosed |
| EP-3310441-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3310773-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| CN-107915728-A | Iap inhibitor | 库里斯公司 | 2018-04-17 | — | — | CN | disclosed |
| US-9932687-B2 | High throughput screening of crystallization of materials | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-04-03 | — | — | US | disclosed |
| CN-107847765-A | The piperidine derivative of 1,4 substitutions | 赛福伦公司 | 2018-03-27 | — | — | CN | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| CN-105143176-B | Xanthomonas albilineans toxin derivant, its purposes and synthesis | 柏林工业大学 | 2018-02-13 | — | — | CN | disclosed |
| US-20170369416-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | UNITED THERAPEUTICS CORPORATION (US) | 2017-12-28 | — | — | US | disclosed |
| CN-107162928-A | The halogenated analogues of antifibrotic agents | 法博太科制药有限公司 | 2017-09-15 | — | — | CN | disclosed |
| US-9758465-B2 | Controlled release pharmaceutical formulations | UNITED THERAPEUTICS CORPORATION (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170166545-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2017-06-15 | — | — | US | disclosed |
| CN-106573904-A | Methods for producing beraprost and its derivatives | 朗格生物技术公共公益股份有限公司 | 2017-04-19 | — | — | CN | disclosed |
| EP-3145919-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | Lung Biotechnology PBC (US) | 2017-03-29 | — | — | EP | disclosed |
| CN-106459039-A | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds as JAK inhibitors | 豪夫迈·罗氏有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016205590-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-20160184824-A1 | HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION OF MATERIALS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | disclosed |
| CN-105407883-A | Controlled release pharmaceutical formulations | UNITED THERAPEUTICS CORP | 2016-03-16 | — | — | CN | disclosed |
| EP-2991639-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | United Therapeutics Corporation (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-1745015-B1 | BICYCLIC AROMATIC SULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-02-17 | — | — | EP | disclosed |
| CN-105228451-A | Process for preparing prostacyclin compounds having a thiol linker and a pegylated form | UNITED THERAPEUTICS CORP | 2016-01-06 | — | — | CN | disclosed |
| CN-105153188-A | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2015-12-16 | — | — | CN | disclosed |
| US-9205423-B2 | High throughput screening of crystallization of materials | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-08 | — | — | US | disclosed |
| WO-2015179427-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2015-11-26 | — | — | WO | disclosed |
| CN-104788313-A | Acceptor material with benzhydryl derivative and PC60BM bis-adduct | XIAN MODERN CHEMISTRY RES INST | 2015-07-22 | — | — | CN | disclosed |
| CN-104781238-A | Pyrazole carboxamide compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2015-07-15 | — | — | CN | disclosed |
| CN-102977188-B | GNRH (gonadotropin-releasing hormone) peptide variants | MEDICAL RES COUNCIL | 2015-07-15 | — | — | CN | disclosed |
| CN-102574843-B | Fused ring analogs of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2015-06-17 | — | — | CN | disclosed |
| EP-2502918-B1 | Pyridazinone Derivatives | CEPHALON INC (US) | 2015-03-25 | — | — | EP | disclosed |
| CN-104271147-A | Cell-penetrating peptides | UNIV PIERRE ET MARIE CURIE PARIS 6 | 2015-01-07 | — | — | CN | disclosed |
| CN-101287755-B | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine | IMMATICS BIOTECHNOLOGIES GMBH | 2014-12-31 | — | — | CN | disclosed |
| US-8912183-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2014179295-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | UNITED THERAPEUTICS CORPORATION (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323567-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | UNITED THERAPEUTICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140296212-A1 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014108526-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF PIPECOLIDEPSIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2014-07-17 | — | — | WO | disclosed |
| EP-2752406-A1 | Substituted pyridazine derivatives which have histamine H3 antagonist activity | CEPHALON, INC. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | CEPHALON, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8709153-B2 | Microfludic protein crystallography techniques | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2252593-B1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8673916-B2 | Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives | CEPHALON, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140041727-A1 | HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION OF MATERIALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-13 | — | — | US | disclosed |
| US-8648067-B2 | Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130310389-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8586588-B2 | Aryl pyridazinone derivatives and their use as H3 receptor ligands | CEPHALON, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8524713-B2 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC (US) | 2013-09-03 | — | — | US | disclosed |
| US-8513232-B2 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-1392484-B1 | HIGH THROUGHPUT SCREENING OF CRYSTALIZATION OF MATERIALS | CALIFORNIA INST OF TECHN (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8410267-B2 | Regioselective reduction of fused pyrrolocarbazoles-5,7-diones | TEVA SANTE (FR) | 2013-04-02 | — | — | US | disclosed |
| US-8382896-B2 | High throughput screening of crystallization materials | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2558114-A2 | CANCER METHODS | Imperial Innovations Limited (GB) | 2013-02-20 | — | — | EP | disclosed |
| US-8314155-B2 | Bicyclic aromatic sulfinyl derivatives | CEPHALON, INC (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2350087-B1 | REGIOSELECTIVE REDUCTION OF FUSED PYRROLOCARBAZOLES-5,7-DIONES | CEPHALON FRANCE (FR) | 2012-11-07 | — | — | EP | disclosed |
| EP-2069312-B1 | PYRIDIZINONE DERIVATIVES | CEPHALON INC (US) | 2012-11-07 | — | — | EP | disclosed |
| CN-102712640-A | Tricyclic heterocyclic compounds, compositions and methods of use thereof | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| US-20120241015-A1 | Microfluidic Protein Crystallography Techniques | NATIONAL INSTITUTES OF HEALTH | 2012-09-27 | — | — | US | disclosed |
| EP-2502918-A1 | Pyridizinone Derivatives | Cephalon, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120238551-A1 | Substituted Phenoxypropylcycloamine Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON FRANCE (FR) | 2012-09-20 | — | — | US | disclosed |
| EP-2492263-A1 | Pyridizinone Derivatives | Cephalon, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8247414-B2 | Pyridizinone derivatives and the use thereof as H3 inhibitors | CEPHALON, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-2250176-B1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8207168-B2 | Pyridazinone derivatives | CEPHALON, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2088150-B1 | Fused pyrrolocarbazoles and methods for the preparation thereof | CEPHALON INC (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2459529-A1 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-8153667-B2 | ATPase inhibitors; Substituted fluorene or benzenerings joined to an alkylene through a sulfone or sulfoxide linkage; without excessive toxicity, irritation, allergic response etc.; sleep dioredrs like excessive sleepiness; Parkinson's disease; Alzheimer's disease; ADD; ADHA; depression, fatigue | CEPHALON, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004231-A1 | Substituted Pyridazine Derivatives | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8084472-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110306522-A1 | MICROFLUIDIC PROTEIN CRYSTALLOGRAPHY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-12-15 | — | — | US | disclosed |
| US-8076331-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110288075-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8052792-B2 | Microfluidic protein crystallography techniques | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2011-11-08 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2011128701-A2 | CANCER METHODS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| US-8034900-B2 | Water-soluble thioester and selenoester compounds and methods for making and using the same | AMYLIN PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110224436-A1 | REGIOSELECTIVE REDUCTION OF FUSED PYRROLOCARBAZOLES-5,7-DIONES | CEPHALON FRANCE (FR) | 2011-09-15 | — | — | US | disclosed |
| EP-2257553-B1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON INC (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2350087-A1 | REGIOSELECTIVE REDUCTION OF FUSED PYRROLOCARBAZOLES-5,7-DIONES | Cephalon France (FR) | 2011-08-03 | — | — | EP | disclosed |
| EP-1496930-B1 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | UNIV CALIFORNIA (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7927422-B2 | Microfluidic protein crystallography | NATIONAL INSTITUTES OF HEALTH (NIH) (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110071131-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-1704148-B1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON INC (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011002984-A1 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2257553-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20100298332-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2252593-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | Cephalon, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2250176-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100280007-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010060968-A1 | REGIOSELECTIVE REDUCTION OF FUSED PYRROLOCARBAZOLES-5,7-DIONES | CEPHALON FRANCE (FR) | 2010-06-03 | — | — | WO | disclosed |
| EP-2192121-A1 | Regioselective reduction of fused pyrrolocarbazoles-5,7-diones | CEPHALON FRANCE (FR) | 2010-06-02 | — | — | EP | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-2088150-A1 | Fused pyrrolocarbazoles and methods for the preparation thereof | Cephalon, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2009097309-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097567-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009097306-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090186888-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090168066-A1 | MICROFLUIDIC PROTEIN CRYSTALLOGRAPHY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2009-07-02 | — | — | US | disclosed |
| EP-2069312-A2 | PYRIDIZINONE DERIVATIVES | Cephalon, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1711499-B1 | FUSED PYRROLOCARBAZOLES AND METHODS FOR THE PREPARATION THEREOF | CEPHALON INC (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090140136-A1 | Method Of Analyzing Protein | NEC CORPORATION (JP) | 2009-06-04 | — | — | US | disclosed |
| US-7514440-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090042907-A1 | Bicyclic aromatic sulfinyl derivatives | CEPHALON, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-7459022-B2 | Microfluidic protein crystallography | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7423176-B2 | Bicyclic aromatic sulfinyl derivatives | CEPHALON, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080070956-A1 | Tricyclic aromatic and bis-phenyl sulfinyl derivatives | CEPHALON, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027041-A1 | Pyridizinone derivatives | CEPHALON, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-7314875-B2 | Tricyclic aromatic and bis-phenyl sulfinyl derivatives | CEPHALON, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7279146-B2 | Crystal growth devices and systems, and methods for using same | FLUIDIGM CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070209574-A1 | MICROFLUIDIC PROTEIN CRYSTALLOGRAPHY TECHNIQUES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070209572-A1 | HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION MATERIALS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070203135-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-7244402-B2 | Microfluidic protein crystallography | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1631597-A4 | DISPLACEABLE LINKER SOLID PHASE CHEMICAL LIGATION | GRYPHON THERAPEUTICS INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7241779-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1616003-A4 | WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | GRYPHON THERAPEUTICS INC (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7217321-B2 | Microfluidic protein crystallography techniques | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-05-15 | — | — | US | disclosed |
| US-7195670-B2 | High throughput screening of crystallization of materials | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1748979-A1 | TRICYCLIC AROMATIC AND BIS-PHENYL SULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1745015-A1 | BICYCLIC AROMATIC SULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060247294-A1 | Novel fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| EP-1711499-A2 | FUSED PYRROLOCARBAZOLES AND METHODS FOR THE PREPARATION THEREOF | CEPHALON, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| EP-1711650-A2 | MICROFLUIDIC PROTEIN CRYSTALLOGRAPHY TECHNIQUES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-10-18 | — | — | EP | disclosed |
| EP-1704148-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20060173159-A1 | Water-soluble thioester and selenoester compounds and methods for making and using the same | ASTRAZENECA PHARMACEUTICALS LP | 2006-08-03 | — | — | US | disclosed |
| EP-1685282-A2 | CRYSTAL GROWTH DEVICES AND SYSTEMS, AND METHODS FOR USING SAME | Fluidigm Corporation (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1496930-A4 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | UNIV CALIFORNIA (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1315738-A4 | EXTENDED NATIVE CHEMICAL LIGATION | GRYPHON THERAPEUTICS INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1631597-A2 | DISPLACEABLE LINKER SOLID PHASE CHEMICAL LIGATION | Gryphon Therapeutics, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1616003-A1 | WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Gryphon Therapeutics, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005100309-A1 | TRICYCLIC AROMATIC AND BIS-PHENYL SULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005100311-A1 | BICYCLIC AROMATIC SULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1589001-A1 | Tricyclic aromatic and bis-phenyl sulfinyl derivatives | CEPHALON, INC. (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050234040-A1 | Tricyclic aromatic and bis-phenyl sulfinyl derivatives | CEPHALON, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| EP-1586561-A1 | Bicyclic aromatic sulfinyl derivatives | CEPHALON, INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050228040-A1 | Bicyclic aromatic sulfinyl derivatives | CEPHALON, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050205005-A1 | Microfluidic protein crystallography | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005063764-A2 | FUSED PYRROLOCARBAZOLES AND METHODS FOR THE PREPARATION THEREOF | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063763-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1549768-A1 | MICROFLUIDIC PROTEIN CRYSTALLOGRAPHY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050143442-A1 | Novel fused pyrrolocarbazoles | CEPHALON, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2005056813-A2 | MICROFLUIDIC PROTEIN CRYSTALLOGRAPHY TECHNIQUES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050137245-A1 | Novel fused pyrrolocarbazoles | CEPHALON, INC. | 2005-06-23 | — | — | US | disclosed |
| US-20050062196-A1 | Microfluidic protein crystallography techniques | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-03-24 | — | — | US | disclosed |
| EP-0944610-B1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050019794-A1 | Crystal growth devices and systems, and methods for using same | FLUIDIGM CORPORATION (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1496930-A2 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | The Regents of The University of California (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004105685-A2 | DISPLACEABLE LINKER SOLID PHASE CHEMICAL LIGATION | GRYPHON THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004104228-A1 | MICROFLUIDIC PROTEIN CRYSTALLOGRAPHY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004094020-A2 | CRYSTAL GROWTH DEVICES AND SYSTEMS, AND METHODS FOR USING SAME | FLUIDIGM CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1392484-A4 | HIGH THROUGHPUT SCREENING OF CRYSTALIZATION OF MATERIALS | CALIFORNIA INST OF TECHN (US) | 2004-07-28 | — | — | EP | disclosed |
| WO-2004061094-A1 | WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | GRYPHON THERAPEUTICS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040115731-A1 | Microfluidic protein crystallography | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-06-17 | — | — | US | disclosed |
| EP-1392484-A2 | HIGH THROUGHPUT SCREENING OF CRYSTALIZATION OF MATERIALS | California Institute of Technology (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2004011424-A2 | SIDE CHAIN ANCHORED THIOESTER AND SELENOESTER GENERATORS | GRYPHON THERAPEUTICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-0667786-B1 | RETRO-, INVERSO-, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGUES | DEAKIN RES LTD (AU) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003086326-A2 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1315738-A1 | EXTENDED NATIVE CHEMICAL LIGATION | Gryphon Therapeutics, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20030061687-A1 | High throughput screening of crystallization materials | CALIFORNIA INSTITUTE OF TECHNOLOGY, A CALIFORNIA CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6534627-B1 | Using FMOC (9-fluorenylmethyloxycarbonyl) and tert-butyl containing compounds as protecting group; efficiency and storage stability | RESEARCH CORPORATION TECNOLOGIES, INC. | 2003-03-18 | — | — | US | disclosed |
| WO-2002082047-A2 | HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION OF MATERIALS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002020557-A1 | EXTENDED NATIVE CHEMICAL LIGATION | GRYPHON THERAPEUTICS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| US-6261569-B1 | ANTIGENS; MIXED WITH CARRIERS; GENETIC ENGINEERING | DEAKIN RESEARCH LIMITED (AU) | 2001-07-17 | — | — | US | disclosed |
| EP-0794959-B1 | AMINO ACIDS FOR MAKING BETIDES AND METHODS OF SCREENING AND MAKING BETIDE LIBRARIES | SALK INST FOR BIOLOGICAL STUDI (US) | 2000-04-05 | — | — | EP | disclosed |
| US-6040480-A | PREPARING 2-(1,1,1-TRIFLUORO-2-HYDROXY-4-CYCLOPROPYL-BUT-3-YN-2-YL),4-CHLOROANILINE; CYCLIZATION; HUMAN IMMUNODEFICIENCY VIRUS (HIV) REVERSE TRANSCRIPTASE INHIBITOR NONTOXIC MAATERIALS; NONCHROMAGRAPHIC PURIFICATION | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| EP-0973755-A1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES VIA NEW INTERMEDIATES | Du Pont Pharmaceuticals Company (US) | 2000-01-26 | — | — | EP | disclosed |
| EP-0962463-A1 | Uncharged morpholino-based polymers having phosphorus-containing chiral intersubunit linkages | ANTIVIRALS INC. (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0944610-A1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5932726-A | VIRICIDE, ENZYME INHIBITOR; 6-CHLORO-4-CYCLOPROPYLETHYNYL4-TRIFLUOROMETHYL-1,4-DIHYDRO2H-3 ,1-BENZOXAZIN-2-ONE | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| US-5925789-A | MULTISTAGE PROCESS WITH AMINATION, DEHYDRATION AND STIRRING TO GIVE AN INTERMEDIATE IN THE SYNTHESIS OF 6-CHLORO-4-CYCLO PROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-2H-3,1-BENZOXAZINE-2-ONE AS AN INHIBITOR OF HIV REVERSE TRANSCRIPTASE | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| US-5877321-A | NEUROKININ RECEPTOR | SANOFI (FR) | 1999-03-02 | — | — | US | disclosed |
| WO-1998045278-A1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES VIA NEW INTERMEDIATES | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5807986-A | GENETIC ENGINEERING | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1998027073-A1 | ASYMMETRIC SYNTHESIS OF BENZOXAZINONES | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| US-5681928-A | ACYLATION, ALKYLATION OF AN AMINOGLYCINE; INSERTION INTO PEPTIDE | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1997-10-28 | — | — | US | disclosed |
| EP-0794959-A1 | AMINO ACIDS FOR MAKING BETIDES AND METHODS OF SCREENING AND MAKING BETIDE LIBRARIES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0667786-A4 | RETRO-, INVERSO-, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGUES. | DEAKIN RES LTD (AU) | 1997-08-06 | — | — | EP | disclosed |
| EP-0777680-A1 | UROKINASE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996040747-A1 | UROKINASE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996018642-A1 | AMINO ACIDS FOR MAKING BETIDES AND METHODS OF SCREENING AND MAKING BETIDE LIBRARIES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5446052-A | Used for treatment of substance p-and neurokinin-dependent pathology such as analgesia and inflmmation | SANOFI (FR) | 1995-08-29 | — | — | US | disclosed |
| EP-0667786-A1 | RETRO-, INVERSO-, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGUES | DEAKIN RESEARCH LIMITED (AU) | 1995-08-23 | — | — | EP | disclosed |
| EP-0496836-B1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RES CORP TECHNOLOGIES INC (US) | 1995-06-14 | — | — | EP | disclosed |
| US-5409926-A | Inhibiting the side effect from angioplasty surgery by administering a biphenyl methyl-6-aminoquinazolinones | MERCK & CO., INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1995003055-A1 | AT-2 ANTAGONIST INHIBITION OF VASCULAR RESTENOSIS | MERCK & CO., INC. (US) | 1995-02-02 | — | — | WO | disclosed |
| US-5385894-A | Disubstituted 6-aminoquinazolinones | MERCK & CO., INC. (US) | 1995-01-31 | — | — | US | disclosed |
| US-5378841-A | Alpha-morpholino ribonucleoside derivatives and polymers thereof | ANTIVIRALS INC. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0623170-A1 | VACCINES BASED ON STREPTOKINASE | PFIZER INC. (US) | 1994-11-09 | — | — | EP | disclosed |
| US-5300648-A | Analgesics, antiinflammatory agents | SOCIETE ANONYME: ELF SANOFI (FR) | 1994-04-05 | — | — | US | disclosed |
| WO-1994005311-A1 | RETRO-, INVERSO-, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGUES | DEAKIN RESEARCH LIMITED (AU) | 1994-03-17 | — | — | WO | disclosed |
| US-5235033-A | ALPHA-MORPHOLINO RIBONUCLEOSIDE DERIVATIVES AND POLYMERS THEREOF | ANTI-GENE DEVELOPMENT GROUP (US) | 1993-08-10 | — | — | US | disclosed |
| WO-1993014209-A1 | VACCINES BASED ON STREPTOKINASE | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
| EP-0496836-A4 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | — | 1993-05-05 | — | — | EP | disclosed |
| WO-1993007872-A1 | LYSOSOMAL ENZYME INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 1993-04-29 | — | — | WO | disclosed |
| EP-0285562-B1 | SYNTHETIC RESIN | CIBA-GEIGY AG (CH) | 1993-04-28 | — | — | EP | disclosed |
| EP-0512902-A1 | Dialkyleneperidino compounds and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-11-11 | — | — | EP | disclosed |
| US-5138037-A | Process for preparing peptide synthons | RHONE-POULENC CHIMIE (FR) | 1992-08-11 | — | — | US | disclosed |
| EP-0496836-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS. | RES CORP TECHNOLOGIES INC (US) | 1992-08-05 | — | — | EP | disclosed |
| US-5093530-A | 2,4-DIMETHOXY-4'-HYDROXY-BENZOPHENONE | CIBA-GEIGY CORPORATION (US) | 1992-03-03 | — | — | US | disclosed |
| US-5077387-A | PROCESS FOR PREPARING PEPTIDE SYNTHONS | RHONE-POULENC CHIMIE (FR) | 1991-12-31 | — | — | US | disclosed |
| WO-1991005564-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-05-02 | — | — | WO | disclosed |
| US-5004781-A | Synthetic polystyrene resin and its use in solid phase peptide synthesis | CIBA-GEIGY CORPORATION (US) | 1991-04-02 | — | — | US | disclosed |
| EP-0382411-A2 | Delivery of cytotoxic agents | ELI LILLY AND COMPANY (US) | 1990-08-16 | — | — | EP | disclosed |
| US-4935536-A | TRIALKOXYBENZYL PROTECTED AMINO ACID | MILLIPORE CORPORATION (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0348892-A2 | Sialic acid-bonded octapeptide and preparation thereof | MECT CORPORATION (JP) | 1990-01-03 | — | — | EP | disclosed |
| US-4859736-A | Synthetic polystyrene resin and its use in solid phase peptide synthesis | CIBA-GEIGY CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| EP-0292228-A2 | Protecting groups for asparagine and glutamine in peptide synthesis | MILLIPORE CORPORATION (US) | 1988-11-23 | — | — | EP | disclosed |
| EP-0285562-A2 | Synthetic resin | CIBA-GEIGY AG (CH) | 1988-10-05 | — | — | EP | disclosed |
| EP-0030920-B1 | ACYL PEPTIDES AND PHARMACEUTICAL PREPARATIONS THEREOF, AS WELL AS THEIR MANUFACTURE AND USE | CIBA-GEIGY AG (CH) | 1984-02-15 | — | — | EP | disclosed |
| EP-0017760-B1 | SOMATOSTATIN ANALOG PEPTIDES, THEIR PREPARATION AND USE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1983-05-11 | — | — | EP | disclosed |
| US-4369179-A | TREATMENT OF DIABETES AND GASTROINTESTINAL BLEEDING WITH SOMATOSTATIN DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1983-01-18 | — | — | US | disclosed |
| US-4316890-A | Peptides and processes for the manufacture thereof | CIBA-GEIGY CORPORATION (US) | 1982-02-23 | — | — | US | disclosed |
| EP-0030920-A2 | Acyl peptides and pharmaceutical preparations thereof, as well as their manufacture and use | CIBA-GEIGY AG (CH) | 1981-06-24 | — | — | EP | disclosed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | disclosed |
| US-4159984-A | METAL AND PROTON DONOR | SHIONOGI & CO., LTD. (JP) | 1979-07-03 | — | — | US | disclosed |
| US-4159981-A | CYCLIC POLYPEPTIDES, DEETHERIFICATION, DEESTERIFICATION | CIBA-GEIGY CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4132712-A | Antibacterial agents | BEECHAM GROUP LIMITED (GB) | 1979-01-02 | — | — | US | disclosed |
| US-3956260-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3934008-A | PEPTIDES, HYPOCALCAEMIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
| US-3934008-A | PEPTIDES, HYPOCALCAEMIC | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143442-A1 | Novel fused pyrrolocarbazoles | PC, PYCR1, CYP11B2 | RAB9A 2196/4885NPC1 132/4885ALDH1A1 467/4885 |
| US-20140323567-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | PTGIR, PTGIS, PTGER1 | RAB9A 1683/4885NPC1 1397/4885ALDH1A1 2245/4885 |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | RAB9A 2624/4885NPC1 198/4885ALDH1A1 110/4885 |
| US-20180265490-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | UMPS, GGPS1, DHPS | RAB9A 4340/4885NPC1 2602/4885ALDH1A1 836/4885 |
| US-20170166545-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | CYP51A1, COASY, BLVRB | RAB9A 3678/4885NPC1 2844/4885ALDH1A1 832/4885 |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | RAB9A 2379/4885NPC1 217/4885ALDH1A1 106/4885 |
| US-11878982-B2 | Spiropiperidine derivatives | FASN, FADS2, SCD5 | RAB9A 2835/4885NPC1 291/4885ALDH1A1 128/4885 |
| US-20140296212-A1 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | RAB9A 1391/4885NPC1 2090/4885ALDH1A1 2032/4885 |
| US-12017989-B2 | Controlled release pharmaceutical formulations | PTGIR, PTGIS, PTGER1 | RAB9A 1683/4885NPC1 1397/4885ALDH1A1 2245/4885 |
| US-20110071131-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | RAB9A 1092/4885NPC1 1888/4885ALDH1A1 1237/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | RAB9A 2624/4885NPC1 198/4885ALDH1A1 110/4885 |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | RAB9A 2624/4885NPC1 198/4885ALDH1A1 110/4885 |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | RAB9A 2196/4885NPC1 132/4885ALDH1A1 467/4885 |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | RAB9A 2624/4885NPC1 198/4885ALDH1A1 110/4885 |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | FASN, FADS1, ASS1 | RAB9A 1578/4885NPC1 106/4885ALDH1A1 170/4885 |
| US-20200062691-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | PTGIR, PTGIS, PTGER1 | RAB9A 1683/4885NPC1 1397/4885ALDH1A1 2245/4885 |
| US-20050137245-A1 | Novel fused pyrrolocarbazoles | PC, PYCR1, CYP11B2 | RAB9A 2196/4885NPC1 132/4885ALDH1A1 467/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | RAB9A 2196/4885NPC1 132/4885ALDH1A1 467/4885 |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | RAB9A 2391/4885NPC1 4122/4885ALDH1A1 2065/4885 |
| US-20120004231-A1 | Substituted Pyridazine Derivatives | HRH3, HRH4, HRH2 | RAB9A 3369/4885NPC1 3816/4885ALDH1A1 2224/4885 |
| US-10246430-B2 | Methods for producing Beraprost and its derivatives | UMPS, GGPS1, DHPS | RAB9A 4340/4885NPC1 2602/4885ALDH1A1 836/4885 |
| US-20100298332-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | RAB9A 1092/4885NPC1 1888/4885ALDH1A1 1237/4885 |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | RAB9A 2624/4885NPC1 198/4885ALDH1A1 110/4885 |
| US-20090042907-A1 | Bicyclic aromatic sulfinyl derivatives | SULT2A1, TPST2, AHR | RAB9A 3000/4885NPC1 400/4885ALDH1A1 141/4885 |
| US-20080027041-A1 | Pyridizinone derivatives | H1-5, H1-3, H1-4 | RAB9A 3714/4885NPC1 2551/4885ALDH1A1 754/4885 |
| US-20050234040-A1 | Tricyclic aromatic and bis-phenyl sulfinyl derivatives | PAH, TYR, AHR | RAB9A 3376/4885NPC1 340/4885ALDH1A1 413/4885 |
| US-20210284651-A1 | Spiropiperidine Derivatives | FASN, FADS2, SCD5 | RAB9A 2835/4885NPC1 291/4885ALDH1A1 128/4885 |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | FASN, CES1, FADS2 | RAB9A 2218/4885NPC1 222/4885ALDH1A1 149/4885 |
| US-20170369416-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | PTGIR, PTGIS, PTGER1 | RAB9A 1683/4885NPC1 1397/4885ALDH1A1 2245/4885 |
| US-20080070956-A1 | Tricyclic aromatic and bis-phenyl sulfinyl derivatives | PAH, TYR, AHR | RAB9A 3376/4885NPC1 340/4885ALDH1A1 413/4885 |
| US-10005753-B2 | Methods for producing beraprost and its derivatives | CYP51A1, COASY, BLVRB | RAB9A 3678/4885NPC1 2844/4885ALDH1A1 832/4885 |
| US-10640481-B2 | Methods for producing Beraprost and its derivatives | UMPS, GGPS1, DHPS | RAB9A 4340/4885NPC1 2602/4885ALDH1A1 836/4885 |
| US-20200031840-A1 | SPIROPIPERIDINE DERIVATIVES | FASN, FADS2, SCD5 | RAB9A 2835/4885NPC1 291/4885ALDH1A1 128/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | RAB9A 2624/4885NPC1 198/4885ALDH1A1 110/4885 |
| US-20090186888-A1 | NOVEL FUSED PYRROLOCARBAZOLES | PC, PYCR1, CYP11B2 | RAB9A 2196/4885NPC1 132/4885ALDH1A1 467/4885 |
| US-20100311752-A1 | Substituted pyridazine derivatives | HRH3, HRH4, HRH2 | RAB9A 3369/4885NPC1 3816/4885ALDH1A1 2224/4885 |
| US-20130310389-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | RAB9A 112/4885NPC1 751/4885ALDH1A1 1732/4885 |
| US-20100280007-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | RAB9A 3149/4885NPC1 3144/4885ALDH1A1 792/4885 |
| US-20110288075-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | RAB9A 3031/4885NPC1 2901/4885ALDH1A1 901/4885 |
| US-20140142088-A1 | PYRIDAZINONE DERIVATIVES | HRH3, HNMT, HRH4 | RAB9A 3102/4885NPC1 2885/4885ALDH1A1 781/4885 |
| US-20240166661-A1 | Spiropiperidine Derivatives | FASN, FADS2, SCD5 | RAB9A 2835/4885NPC1 291/4885ALDH1A1 128/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | RAB9A 3149/4885NPC1 3144/4885ALDH1A1 792/4885 |
| US-20120238551-A1 | Substituted Phenoxypropylcycloamine Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | RAB9A 1391/4885NPC1 2090/4885ALDH1A1 2032/4885 |
| US-20060173159-A1 | Water-soluble thioester and selenoester compounds and methods for making and using the same | SCLY, TST, SELENOI | RAB9A 3892/4885NPC1 4072/4885ALDH1A1 2859/4885 |
| US-10494327-B2 | Controlled release pharmaceutical formulations | PTGIR, PTGIS, PTGER1 | RAB9A 1683/4885NPC1 1397/4885ALDH1A1 2245/4885 |
| US-20210317066-A1 | CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS | PTGIR, PTGIS, PTGER1 | RAB9A 1683/4885NPC1 1397/4885ALDH1A1 2245/4885 |
| US-20060247294-A1 | Novel fused pyrrolocarbazoles | PC, PYCR1, CYP11B2 | RAB9A 2196/4885NPC1 132/4885ALDH1A1 467/4885 |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | RAB9A 2624/4885NPC1 198/4885ALDH1A1 110/4885 |
| US-20190202797-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | UMPS, GGPS1, DHPS | RAB9A 4340/4885NPC1 2602/4885ALDH1A1 836/4885 |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | RAB9A 2560/4885NPC1 172/4885ALDH1A1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.